# Deltex Medical Group plc releases non-invasive High Definition Impedance Cardiography module

- Link: https://www.directorstalkinterviews.com/deltex-medical-group-plc-releases-non-invasive-high-definition-impedance-cardiography-module/412728552
- Published: 2017-05-04T07:09:31+01:00
- Author: Giles Arbor

**Deltex Medical Group plc** (LON:DEMG), the global leader in Oesophageal Doppler
Monitoring (“ODM”), announces the launch of non-invasive High Definition Impedance
Cardiography (HD-ICG) in the UK, as an additional module on its CardioQ-ODM+ monitoring
platform.

HD-ICG provides a continuous indirect measurement of central blood flow. An electrical
field is set up across the patient’s chest following placement of a single patient
disposable set of sensors on the abdomen. The disruption to this field caused by
the heart pumping blood is measured and used to calculate cardiac output variables
using an established nomogram. The sensors are connected to the Deltex monitor via
a small console which also powers the sensors and values are displayed on specially
designed screens on the CardioQ-ODM+.

The HD-ICG system is non-invasive making it ideal for monitoring patients in both
critical care and surgery who are awake and do not tolerate ODM probes. Adding it
to the CardioQ-ODM+ increases the numbers of patients the Company can treat.

The Company is launching the new product, which is CE marked, immediately in the
UK and plans to introduce it into select overseas markets as the relevant foreign
language versions are completed over the course of the year. The software upgrade
necessary to add the new product to the US version of the CardioQ-ODM+ requires 
separate regulatory clearance which the Company is pursuing with the manufacturer’s
support.

**Heads of agreement**

Deltex has signed heads of agreement with the manufacturer giving it exclusive rights
to sell HD-ICG into critical care and surgical settings initially in a number of
key Deltex markets including the UK, France, Scandinavia, Spain and Peru with mechanisms
in place for additional territories in due course. Release in the USA is also intended
to be on an exclusive basis subsequent to gaining regulatory approval.

The agreement is for an initial three years with roll-over provisions and secures
Deltex’s ability to support the modules for ten years after any termination.

Investor open day demonstration

HD-ICG will be demonstrated at the investor open day at Deltex’s Chichester facility
on Friday 5 May. Investors or potential investors wishing to attend this meeting
who have not already registered should email investorinfo@deltexmedical.com.

> **Ewan Phillips, Deltex Medical Group plc Chief Executive, commented:** “The addition
> of High Definition Impedance Cardiography to our monitoring platform is an exciting
> development. It gives us an easy to use non-invasive cardiac output monitoring
> technology which is broadly complementary to our exisiting ODM technology.
> “Following the 2012 addition of Pulse Pressure Waveform Analysis to CardioQ-ODM
> +, we are now able to offer our customers all three of the leading advanced haemodynamic
> monitoring technologies on a single platform. This means clinicians can choose
> the most appropriate technology for their monitoring requirements across the whole
> hospital.”

Share on:
